A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum
April 10th, 2018
8.4K views
We describe a simple and easy protocol for measuring antibody dependent enhancement of infection by Zika virus convalescent serum using Dengue virus Reporter Viral Particles.
Overview
This article presents a protocol for measuring antibody dependent enhancement of infection by Zika virus convalescent serum using Dengue virus Reporter Viral Particles. The method aims to assess the ability of sera from Zika virus infected rhesus macaques to enhance dengue virus infection in vitro.
Key Study Components
Area of Science
- Infectious diseases
- Immunology
- Virology
Background
- Antibody dependent enhancement (ADE) can complicate viral infections.
- Zika virus infection may lead to cross-reactive antibodies that affect dengue virus.
- Understanding ADE is crucial for vaccine development and public health.
- This study utilizes a straightforward and effective method for investigation.
Purpose of Study
- To evaluate the role of Zika virus convalescent serum in enhancing dengue virus infection.
- To provide insights into the mechanisms of ADE in viral infections.
- To establish a reliable protocol for future research in this area.
Methods Used
- Thawing serum samples at room temperature.
- Transferring serum samples to sterile tubes.
- Heating and activating serum samples at 56 degrees Celsius for 30 minutes.
- Using Dengue virus Reporter Viral Particles for infection assays.
Main Results
- The protocol is simple and high throughput.
- It allows for the assessment of serum's capacity to mediate ADE.
- Results can inform future studies on Zika and dengue interactions.
- The method is demonstrated by a graduate student in a laboratory setting.
Conclusions
- This study provides a valuable tool for investigating ADE in viral infections.
- Understanding the interaction between Zika and dengue viruses is essential for public health.
- The protocol can be adapted for further research in related fields.
Frequently Asked Questions
What is antibody dependent enhancement?
Antibody dependent enhancement (ADE) is a phenomenon where antibodies facilitate viral entry into cells, potentially worsening the infection.
Why is this study important?
It helps clarify the role of Zika virus antibodies in enhancing dengue virus infections, which is crucial for vaccine development.
What are Dengue virus Reporter Viral Particles?
These are modified viral particles used to study dengue virus infection in vitro.
How does the protocol improve research?
The protocol is high throughput, simple, and easy to perform, making it accessible for various research settings.
Who conducted the study?
The study was conducted by William Valiant, a graduate student in infectious diseases.
Executive Industry Relevance
Antibody dependent enhancement (ADE) poses a significant risk in flavivirus vaccine development, where cross-reactive antibodies may exacerbate infection rather than confer protection. This flow cytometry-based assay provides a quantitative, high-throughput method to assess ADE potential using reporter viral particles, enabling early de-risking of vaccine candidates. By eliminating the need for live virus and plaque assays, the method supports scalable screening in discovery and preclinical workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses regarding cross-reactive antibody mechanisms in flavivirus pathogenesis.
- Operational Value: Supports functional validation of antibody-mediated enhancement phenotypes using quantifiable GFP readouts.
- Predictive Value: Generates dose-response data (fold enhancement vs. dilution) to inform target confidence and prioritize immunogen design.
Screening & Assay Development
- Assay Readiness: Produces standardized, reproducible quantitative outputs via flow cytometry, suitable for hit confirmation in antibody screening campaigns.
- Scalability: Compatible with 96-well formats and multichannel pipetting, enabling medium-throughput evaluation of serum or antibody libraries.
- Adaptability: Easily modified for other flaviviruses (YFV, WNV, JEEV) when corresponding reporter viral particles are available, increasing platform utility.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery-phase mechanism evaluation with preclinical risk assessment by modeling human-relevant ADE conditions using convalescent serum.
- Disease-Relevant System: Uses K562 cells, a well-established model for FcγR-mediated flavivirus infection, enhancing physiological relevance of enhancement measurements.
- Mechanistic De-risking: Allows evaluation of enhancement across multiple dengue serotypes, supporting broad-spectrum safety profiling of vaccine-induced immune responses.
Pipeline & Workflow Integration
The assay fits within the discovery to preclinical continuum, particularly after initial antibody generation and before in vivo challenge studies, where ADE risk must be empirically evaluated.
- Discovery Biology: Supports hypothesis testing of antibody effector functions and pathway modulation via FcγR engagement in enhancement assays.
- Screening: Delivers quantitative, normalized infection metrics (GFP+ %) that enable comparison across conditions and samples.
- Analytics: Generates fold-enhancement calculations and statistical outputs (ANOVA, Tukey’s) for rigorous inter-group comparison and hit selection.
- Translational Research: Connects in vitro findings to preclinical decision-making by providing empirical ADE thresholds for go/no-go criteria.
- Enterprise Reuse: Establishes a modular, reusable platform for flavivirus ADE assessment across multiple targets and programs.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in antibody-mediated pathogenicity by providing direct, quantifiable enhancement measurements.
- Operational Value: Ensures standardization and reproducibility through minimal cell handling, fixed incubation times, and automated flow cytometry readouts.
- Strategic Value: Improves go/no-go decisions by identifying enhancement liabilities early, reducing late-stage attrition due to unforeseen ADE risks.
- Portfolio Impact: Enables risk-adjusted prioritization of vaccine candidates based on empirical ADE profiles across dengue serotypes.
Implementation Considerations
- Requires expertise in flow cytometry operation, compensation, and gating strategy for single-cell and fluorescence analysis.
- Dependent on access to biosafety level 2 (BSL-2) facilities for handling convalescent serum and reporter viral particles.
- Needs standardized reagent preparation, including heat-inactivated serum, RPMI 10 media, and trypsin-free cell handling to maintain K562 viability.
- Adaptation to new flaviviruses requires validation of corresponding reporter viral particles and optimization of infection conditions in K562 cells.
- Practical limitation: Assay duration (~48 hours) may restrict ultra-high-throughput use compared to luminescence-based alternatives, though it avoids live virus handling.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in ADE assays?
Null hypothesis testing determines whether observed enhancement exceeds background infection levels, ensuring that measured GFP+ signals reflect true antibody-dependent effects rather than variability. In this assay, statistical comparison using ANOVA and Tukey’s post-hoc test validates significant enhancement at specific serum dilutions, supporting confident target mechanism conclusions.
How does independent variable isolation fit the discovery pipeline for ADE assessment?
Isolating the independent variable (e.g., serum dilution or antibody specificity) allows researchers to attribute changes in infection directly to the test condition, eliminating confounding factors. This approach was used here by testing serial dilutions of ZIKV convalescent serum against DENV RVPs, enabling clear interpretation of enhancement potency and specificity.
What quantitative dependent variable measurements enable ADE assessment in this assay?
The percentage of GFP-positive cells serves as the quantitative dependent variable, directly reflecting DENV RVP infection levels in K562 cells under each condition. This metric allows calculation of fold enhancement relative to no-serum controls, providing a scalable, objective readout for comparing enhancement across serum samples and dilutions.
Why do replication requirements matter for cross-functional collaboration in ADE studies?
Replication ensures that ADE observations are consistent across experiments, building confidence in data shared between discovery, preclinical, and translational teams. Consistent enhancement trends across replicates support reliable handoff for further testing or decision-making in vaccine development programs.
What statistical analysis capabilities are required before implementing this ADE assay in a discovery setting?
The assay requires post-acquisition statistical tools to calculate mean GFP+ percentages, perform fold-enhancement normalization, and conduct group comparisons using ANOVA with post-hoc testing. These capabilities are essential to distinguish significant enhancement from noise and support data-driven go/no-go decisions in early-stage projects.
